MEDA PHARMA GMBH & CO. KG
Patent Owner
Stats
- 46 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- Mar 12, 2015 most recent publication
Details
- 46 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 1,145 Total Citation Count
- Mar 24, 1986 Earliest Filing
- 27 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
8518918 Combination of anticholinergics, β2-adrenoceptor agonists, antileukotrienes (leukotriene receptor antagonists), glucocorticoids and/or phosphodiesterase 4 inhibitors for the treatment of inflammatory diseasesSep 23, 11Aug 27, 13[A61K]
8268864 Combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseasesMar 16, 06Sep 18, 12[A61K, A01N, C07D]
8097605 Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseaseFeb 03, 09Jan 17, 12[A61K]
8048910 Combination of R,R-glycopyrrolate, rolipram, and budesonide for the treatment of inflammatory diseasesDec 21, 06Nov 01, 11[A61K]
7985766 Combination of anticholineric and β mimetics for the treatment of respiratory diseasesJul 30, 07Jul 26, 11[A61K]
7569598 Process for the preparation of the R,R (or S,S) configured glycopyrronium stereoisomerDec 18, 03Aug 04, 09[A61K, C07D]
7253182 Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicamentsJun 23, 03Aug 07, 07[A61K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
8557851 Combinations of flupirtine and sodium channel inhibiting substances for treating painsExpiredMar 12, 09Oct 15, 13[A61K]
2009/0142,407 Solid peptide preparations for inhalation and their preparationAbandonedJun 04, 08Jun 04, 09[A61K]
2008/0095,741 R-(+)-alpha-liponic acid for the prevention of diabetesAbandonedApr 18, 07Apr 24, 08[A61K, A61P]
2005/0288,265 Novel combination of glucocorticoids and pde-4 inhibitors for treating respiratory diseases, allegic diseases, asthma and copdAbandonedFeb 09, 05Dec 29, 05[A61K]
2005/0222,102 Treatment of rhinitis with anticholinergics alone or in combination with antihistamines, phosphodiesterase 4 inhibitors, or corticosteroidsAbandonedFeb 07, 05Oct 06, 05[A61K]
2005/0175,547 Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseasesAbandonedFeb 07, 05Aug 11, 05[A61K, A61L]
2005/0175,548 Combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPDAbandonedFeb 07, 05Aug 11, 05[A61K, A61L]
2005/0175,549 Novel combination of anticholinergic and ss mimetics for the treatment of respiratory diseasesAbandonedFeb 07, 05Aug 11, 05[A61K, A61L]
2005/0089,559 Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating painsAbandonedDec 05, 03Apr 28, 05[A61K]
2005/0014,677 Solid peptide preparations for inhalation and their preparationAbandonedMar 23, 04Jan 20, 05[A61K]
6300370 Camomile oils having a high content of natural poly-ynes and process for their preparationExpiredJun 10, 98Oct 09, 01[A61K]
6013815 Production and use of salts of 6,8-bis (amidiniumthio)-octanoic acidExpiredMar 18, 98Jan 11, 00[C07B]
5998403 Salts of azelastine having improved solubility useful at providing a cytoprotective effectExpiredJul 28, 98Dec 07, 99[A61K]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.